With an average of 19 years of nursing experience, Nurse Ambassadors are the heart of HUMIRA Complete.2 From the moment your patients enroll in HUMIRA Complete, a Nurse Ambassador is available to listen, to encourage them to make their own decisions, and to motivate them to reach their goals. Ambassadors reinforce your treatment plan and help patients stay on track with their prescribed treatment.
Ambassadors can help by
*Ambassadors do not provide medical advice and are trained to direct patients to speak with their healthcare professional about any treatment-related questions, including further referrals.
[Text on Screen and Spoken] This demonstration video offers you help and guidance for injecting with the HUMIRA® Pen. Watch it and read the entire Patient Instructions for Use found in your HUMIRA package. Don’t try to inject HUMIRA yourself until your doctor has decided you can, and you’ve been shown the right way to give injections.
Throughout this video, you will hear from actual patients. Individual experiences may vary.
[SUPER] HUMIRA logo
[Text on Screen] Please see Uses and Important Safety Information within the website. Please see accompanying full Prescribing Information, including Patient Instructions for Use and Medication Guide, and discuss with your doctor.
[SUPER] HUMIRA Complete nmemonic
[Text on Screen] Injecting HUMIRA with HUMIRA Complete. Resources designed around you
JANET:
Hi, how are you? I’m Janet. And I know that there are a million things you’d rather be doing right now than learning about injecting your medication...I get it. Before we start, I want you to know that there are a lot more ways HUMIRA Complete can help you out than with this video. Because, well, let’s be real...there’s more to making HUMIRA a routine part of your life than just learning how to inject.
If you are concerned about being able to afford your medication, or have questions about insurance, or are wondering how you can do this on your own, HUMIRA Complete can help get you the answers you need when you need them. You even have a dedicated Nurse Ambassador available to you. Whether you are just starting or have been taking it awhile, HUMIRA Complete is there for you.
[Text on Screen] Call 1.800.4HUMIRA
Request a HUMIRA Complete Nurse Ambassador* at 1.800.4HUMIRA
*Ambassadors do not give medical advice and will direct you to your health care professional for any treatment-related questions, including further referrals.
Everyone has a different perspective about injecting and throughout this video you will hear from some actual patients.
[Text on Screen] Visit HUMIRAComplete.com to request an Injection Training Kit
LINDSEY:
I was very hesitant. My first thought was “You’ve been terrified of needles since you were a child.”
STEVEN:
Obviously, it involves a little bit more than just taking a pill and what it would feel like.
DANAY:
It’s okay to be nervous, it’s okay to feel nervous. But, if this is something that’s gonna help me continue to move forward, why not give it a try?
LAURA:
Luckily, my Nurse Ambassador—she was awesome. So she came and she really was patient, took her time with me.
MICHAEL:
They have been very good about calling and keeping up with what’s going on.
JANET:
So, let’s clear some things up. Ready? Let’s do this.
First, wash your hands and get the things you need. And settle in a place where you feel relaxed.
[Text on Screen] Store HUMIRA in the refrigerator until time of use.
[Text on Screen] Do not use HUMIRA if frozen, even if it has been thawed. Do not use if the medicine has passed the expiration date.
If it’s more comfortable for you, take your HUMIRA out of the fridge and leave it at room temp fifteen to thirty minutes before you inject.
[Text on Screen] HUMIRA should not be frozen or exposed to direct sunlight.
LAURA:
Like, I think having the routine in the beginning until I was comfortable made a lot of sense for me.
LINDSEY:
I lay everything out, I plan which side I’m going to inject, and I think the process actually calms me down.
DANAY:
I knew that one day I’m gonna have to do it on my own so, I just sucked it up and I did it.
JANET:
There’s an alcohol swab that’s included inside the package, a cotton ball (you can also use a gauze pad), a sharps container (that looks like this), and of course, the HUMIRA Pen. Your doctor may have prescribed you one of two Pens. The differences you can see here are the viewing window and the caps. Both Pens work the same way. Now, check the Pen. There’s a large number one on the gray cap and a large number two on the plum-colored cap. You can’t miss ‘em. Look at the Pen with the gray cap pointing up to make sure that the liquid is clear and colorless. If the liquid is cloudy, has an unusual color, or has flakes or specks in it, you shouldn’t use it. Use another Pen in the fridge if you have one and call your pharmacy. If you see a few bubbles, no problem. And be sure to check the medicine’s expiration date. You can find what we’re about to cover inside the package.
I’ll break this down in 4 simple steps. Let’s call them the “4 Ps”.
[Text on Screen] 4Ps
[Text on Screen] PICK THE INJECTION SITE
To pick your site, rotate each time at least one inch from the previous injection site; you can inject in the right or left thigh or on your stomach.
[Text on Screen] Injectable Areas
[Text on Screen] A new injection should be at least 1 inch away from the site you chose the time before
If you choose the lower stomach area, make sure it’s at least 2 inches away from your belly button.
[Text on Screen] 2 inches
Clean the site with an alcohol swab. You shouldn’t inject through clothing. And don’t inject into any skin that doesn’t look normal.
[Text on Screen] Do not inject into skin that is sore, bruised, red, hard, scarred, raised, thick, has scaly patches, lesions, or stretch marks.
[Text on Screen]: PULL THE CAPS OFF
JANET:
So now, pick up the Pen with the gray cap pointing up, holding the middle of the Pen with one hand. With your other hand, pull that gray cap straight off. No need to recap the Pen, and be careful not to touch the needle. If a few drops of liquid come out of the needle, no worries. Now, from the bottom of the Pen, pull the plum-colored cap off, and you’ll see a plum button. Then flip the Pen so that the plum activator button is now pointing up and hold it so you can see the window. Don’t press the button just yet. Now, you’re just about ready to inject. If you’re still a little nervous...I totally get it.
DANAY:
Try to think about something else, like TV or something to distract you.
STEVEN:
Just listen to your favorite music.
MICHAEL:
I think the Pen, when you do not see the needle, would help anyone who is afraid of needles.
LAURA:
Honestly, and remembering to breathe. That’s huge!
DANAY:
Take a deep breath in...
STEVEN:
And then exhale.
DANAY:
And I just did it. One, two, three, and it was over!
[Text on Screen] PLACE THE WHITE END OF THE PEN ON THE SITE
JANET:
With your free hand, squeeze the area of skin that you’ve cleaned and hold it firmly until the injection is complete.
[Text on Screen] PRESS THE PLUM-COLORED BUTTON
Place the white needle sleeve of the Pen straight at a ninety-degree angle and flat against your skin.
[Text on Screen] 90°
And press the plum activator button with your thumb to start the injection. Hear that? [SFX: Pen “CLICK”] That’s the click you’ll hear that signals the start of the injection. You may actually feel the medicine going in. Don’t let it startle you. And we’re off...
[Text on Screen] It is important that you firmly push the Pen down all the way against the injection site before starting the injection. Keep pushing down to prevent the Pen from moving away from the skin during the injection.
Continue to press the button and push the Pen against your squeezed, raised skin for 10 seconds to make sure all the medicine has been released from the Pen. You’ll know the injection is finished when the yellow indicator in the window has stopped moving. You're good to go.
[Text on Screen counts down]: Injection is complete when the yellow indicator has stopped moving
Pull the Pen away from your skin...
[Text on Screen counts down]: Injection is complete when the yellow indicator has stopped moving. This could take 10-15 seconds depending on the dose.
Drop the Pen into a sharps container immediately.
Instead of rubbing the site, gently press a cotton ball (or gauze) for ten seconds. There may be a small amount of liquid on the injection site, which is totally normal.
[Text on Screen] There may be pain, redness, rash, swelling, itching, or bruising. If it doesn’t go away within a few days or gets worse, call your doctor right away.
STEVEN:
It definitely hurt less than I had imagined it.
LAURA:
All those nerves I had in the beginning now it’s kind of almost nothing.
JANET:
In a nutshell, here’s what we just did:
[Text on Screen] 4Ps
LINDSEY
I made it through it.
MICHAEL
You just have to get over that fear.
DANAY
I have confidence, I know what I’m doing, I’m a pro, that’s what—I’m a pro!
JANET
The HUMIRA Complete Sharps Disposal and Mail-back Service ensures your HUMIRA is disposed of safely and in a socially responsible way.
[Text on Screen] You can get a sharps container from HUMIRA Complete shipped to your home at no additional cost
[Text on Screen] For more information about sharps disposal, go to the FDA website: www.fda.gov/safesharpsdisposal
LINDSEY:
When I’m finished with my HUMIRA Pen, I put it in a sharps container.
LAURA:
I actually keep it on a shelf in my bedroom, so it is out of reach. When it starts getting full, I call and they send me a new one and the box to send it back.
[Text on Screen] For sharps container, call 1.800.4HUMIRA or visit HUMIRA.com
DANAY
It doesn’t cost me anything to send back the sharps container, which is good.
STEVEN
The HUMIRA Complete app, it keeps on a two-week schedule.
[Text on Screen] Get it in the App Store or Google Play
Search HUMIRA Complete.
[HUMIRA Complete plum icon]
LAURA:
It gave me every tool that I need to understand what I’m doing and how to do it.
MICHAEL
They will text that I’ve got an injection coming up.
[Text on Screen] Schedule reminder calls, email, or texts on HUMIRA.com or call 1.800.4HUMIRA
DANAY
It feels great to be able to be in control of my own medicine.
LINDSEY
I completely own this disease, as well as my own health.
JANET
OK, that’s it. If you have any questions, call your doctor. You can also call HUMIRA Complete at 1.800.4HUMIRA or your Nurse Ambassador. And you can always refer to this video to cover the basics. You’ve got this.
[SUPER] HUMIRA Complete logo
[Text on Screen] Call 1.800.4HUMIRA
[Super] HUMIRA Complete nmemonic
[Super] HUMIRA Complete LOGO
[Text on Screen] Please see Uses and Important Safety Information within the website. Please see accompanying full Prescribing Information, including Patient Instructions for Use and Medication Guide, and discuss with your doctor.
[Text on Screen] Safety Considerations1
[Text on Screen and Spoken] Common side effects of HUMIRA include injection site reactions (pain, redness, rash, swelling, itching, or bruising), upper respiratory infections (sinus infections), headaches, rash, and nausea. These are not all of the possible side effects with HUMIRA. Tell your doctor if you have any side effect that bothers you or that does not go away.
[Text on Screen]You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit abbvie.com/myabbvieassist to learn more.
[Spoken] You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
[Text on Screen] Reference: 1. HUMIRA Injection [package insert]. North Chicago, IL: AbbVie Inc.
US-HUM-200154
Injection training videos and kit
HUMIRA Complete provides ongoing injection training. While patients will get their initial injection from you, your staff, or their Nurse Ambassador, HUMIRA Complete can help reinforce it. Patients can choose from personalized training provided by a nurse, or online training videos.
Patients can request an Injection Training Kit by visiting HUMIRA.com, using the Complete App, or by calling 1.800.4HUMIRA (1.800.448.6472).†
†Nurses are available at 1.800.4HUMIRA (1.800.448.6472) for immediate assistance Monday through Friday, from 8 AM to 8 PM ET. At all other times, a nurse will return your call within 1 hour.
Your patients could get HUMIRA for as little as $5 a month.‡
HUMIRA Complete can help patients understand their insurance coverage and assist in identifying ways to save on HUMIRA, including the HUMIRA Complete Savings Card.
The HUMIRA Complete Savings Card can help your eligible commercially insured patients get HUMIRA for as little as $5 for each dose. Your patients can access the Savings Card by creating an account on HUMIRA.com, by downloading the Complete App, or using the downloadable forms linked below.
‡Terms and Conditions apply. This benefit covers HUMIRA® (adalimumab) alone or, for rheumatology patients, HUMIRA plus one of the following medications: methotrexate, leflunomide (Arava®), or hydroxychloroquine (Plaquenil®). Eligibility: Available to patients with commercial prescription insurance coverage for HUMIRA who meet eligibility criteria. Co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law or by the patient’s health insurance provider. If at any time a patient begins receiving prescription drug coverage under any such federal, state, or government-funded healthcare program, patient will no longer be able to use the HUMIRA Complete Savings card and patient must call HUMIRA Complete at 1-800-4HUMIRA to stop participation. Patients residing in or receiving treatment in certain states may not be eligible. Patients may not seek reimbursement for value received from the HUMIRA Complete Program from any third-party payers. Offer subject to change or discontinuance without notice. Restrictions, including monthly maximums, may apply. Patients who are members of insurance plans that claim to reduce or eliminate their patients' out of pocket co-pay, co-insurance, or deductible obligations for certain prescription drugs based upon the availability of, or patient's enrollment in, manufacturer sponsored co-pay assistance for such drugs (often termed "maximizer" programs) will have an annual maximum program benefit of $6,000.00 per calendar year. This assistance offer is not health insurance. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html
Arava and Plaquenil are registered trademarks of their respective owners.
Do you have patients who are uninsured or unemployed?
Patients who are uninsured or unemployed may be eligible to receive HUMIRA at no cost from myAbbVie Assist or another foundation.
The HUMIRA Complete App helps patients stay on track with their prescribed treatment through:
SERIOUS INFECTIONS
Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Discontinue HUMIRA if a patient develops a serious infection or sepsis.
Reported infections include:
Carefully consider the risks and benefits of treatment with HUMIRA prior to initiating therapy in patients: 1. with chronic or recurrent infection, 2. who have been exposed to TB, 3. with a history of opportunistic infection, 4. who resided in or traveled in regions where mycoses are endemic, 5. with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including HUMIRA. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including HUMIRA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants.
HYPERSENSITIVITY
HEPATITIS B VIRUS REACTIVATION
NEUROLOGIC REACTIONS
HEMATOLOGIC REACTIONS
CONGESTIVE HEART FAILURE
AUTOIMMUNITY
IMMUNIZATIONS
ADVERSE REACTIONS
US-HUM-190292
References:
You are about to enter a site that is for U.S. Healthcare Professionals Only.
By selecting "Yes" below, you certify that you are a Healthcare Professional and that you wish to proceed to the Healthcare Professionals Only section on the AbbVie Medical Information site. Products or treatments described on this site are available in the U.S. but may not be available in all other countries. I am a licensed Healthcare Professional and wish to proceed to the Healthcare Professionals Only AbbVie Medical Information Site.
US-HUM-190186
Leaving AbbVie Web Site
You are leaving the AbbVie Web site and connecting to a site that is not under the control of AbbVie. AbbVie is not responsible for the contents of any such site or any further links from such site. AbbVie is providing these links to you only as a convenience and the inclusion of any link does not imply the endorsement of the linked site by AbbVie. You should also be aware that the linked site may be governed by its own set of terms and conditions and privacy policy for which AbbVie has no responsibility.
Conversely, the presence of this link does not imply the linked site's endorsement of HUMIRA.com or AbbVie.
Do you wish to leave this site?
US-HUM-190186
Serious Infections: Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue HUMIRA if a patient develops a serious infection or sepsis. Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including HUMIRA. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including HUMIRA. These cases have had a very aggressive disease course and have been fatal.
Serious Infections: Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including HUMIRA. Postmarketing cases of
Serious Infections: Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue HUMIRA if a patient develops a serious infection or sepsis. Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including HUMIRA. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including HUMIRA. These cases have had a very aggressive disease course and have been fatal.
Serious Infections: Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including HUMIRA. Postmarketing cases of
SERIOUS INFECTIONS
Patients treated with HUMIRA are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.
Discontinue HUMIRA if a patient develops a serious infection or sepsis.
Reported infections include:
Carefully consider the risks and benefits of treatment with HUMIRA prior to initiating therapy in patients: 1. with chronic or recurrent infection, 2. who have been exposed to TB, 3. with a history of opportunistic infection, 4. who resided in or traveled in regions where mycoses are endemic, 5. with underlying conditions that may predispose them to infection. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with HUMIRA, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy.
MALIGNANCY
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including HUMIRA. Postmarketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including HUMIRA. These cases have had a very aggressive disease course and have been fatal. The majority of reported TNF blocker cases have occurred in patients with Crohn’s disease or ulcerative colitis and the majority were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. It is uncertain whether the occurrence of HSTCL is related to use of a TNF blocker or a TNF blocker in combination with these other immunosuppressants.
HYPERSENSITIVITY
HEPATITIS B VIRUS REACTIVATION
NEUROLOGIC REACTIONS
HEMATOLOGIC REACTIONS
CONGESTIVE HEART FAILURE
AUTOIMMUNITY
IMMUNIZATIONS
ADVERSE REACTIONS
US-HUM-190292